SG10201811203TA - Protocols for treatment of major depressive disorder (mdd) - Google Patents

Protocols for treatment of major depressive disorder (mdd)

Info

Publication number
SG10201811203TA
SG10201811203TA SG10201811203TA SG10201811203TA SG10201811203TA SG 10201811203T A SG10201811203T A SG 10201811203TA SG 10201811203T A SG10201811203T A SG 10201811203TA SG 10201811203T A SG10201811203T A SG 10201811203TA SG 10201811203T A SG10201811203T A SG 10201811203TA
Authority
SG
Singapore
Prior art keywords
mdd
depressive disorder
major depressive
protocols
treatment
Prior art date
Application number
SG10201811203TA
Inventor
Karl Johe
Original Assignee
Neuralstem Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neuralstem Inc filed Critical Neuralstem Inc
Publication of SG10201811203TA publication Critical patent/SG10201811203TA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

PROTOCOLS FOR TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD) Although it is known that certain benzylpiperazine-aminopyridines or open chain forms thereof are effective in stimulating neural growth in in vitro tests, it has now been surprisingly found that administering these compounds in a dosage range of mg/day - 130 mg/day over 25-35 days is effective in treating Major Depressive Disorder (MDD) such that statistically significant results can be obtained with samples of only six subjects. [Figure 1A] 12
SG10201811203TA 2014-06-16 2015-06-15 Protocols for treatment of major depressive disorder (mdd) SG10201811203TA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462012880P 2014-06-16 2014-06-16

Publications (1)

Publication Number Publication Date
SG10201811203TA true SG10201811203TA (en) 2019-01-30

Family

ID=54835238

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201811203TA SG10201811203TA (en) 2014-06-16 2015-06-15 Protocols for treatment of major depressive disorder (mdd)
SG11201610536XA SG11201610536XA (en) 2014-06-16 2015-06-15 Protocols for treatment of major depressive disorder (mdd)

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201610536XA SG11201610536XA (en) 2014-06-16 2015-06-15 Protocols for treatment of major depressive disorder (mdd)

Country Status (9)

Country Link
US (1) US9572807B2 (en)
EP (1) EP3154545A4 (en)
JP (1) JP6675330B2 (en)
KR (1) KR102475363B1 (en)
CN (1) CN106572996B (en)
AU (1) AU2015277406B2 (en)
CA (1) CA2952452C (en)
SG (2) SG10201811203TA (en)
WO (1) WO2015195567A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7204640B2 (en) * 2016-09-12 2023-01-16 ニューラルステム・インコーポレーテッド Improvement of neuropathy associated with diabetes
US10413534B2 (en) * 2017-02-13 2019-09-17 Neuralstem, Inc. Amelioration of certain deficiencies due to stroke
US20220387424A1 (en) 2021-06-03 2022-12-08 Alto Neuroscience, Inc. Method of treatment of depressed patients with poor cognition and selection of other patients benefiting from a benzylpiperazine-aminopyridine agent
WO2024123695A1 (en) * 2022-12-05 2024-06-13 Alto Neuroscience, Inc. Effective treatment of depression in patients having impaired learning and/or memory or certain eeg characteristics with a benzylpiperazine-aminopyridine agent

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040185429A1 (en) * 2002-12-09 2004-09-23 Judith Kelleher-Andersson Method for discovering neurogenic agents
US20140350029A1 (en) * 2011-12-02 2014-11-27 Dainippon Sumitomo Pharma Co., Ltd. Lurasidone novel dosage regimens and use thereof for the treatment, prevention, and/or management of at least one cns disorder

Also Published As

Publication number Publication date
CN106572996B (en) 2020-04-07
EP3154545A4 (en) 2017-12-20
EP3154545A1 (en) 2017-04-19
AU2015277406A1 (en) 2017-01-12
US20150359792A1 (en) 2015-12-17
CA2952452C (en) 2022-07-26
CA2952452A1 (en) 2015-12-23
JP6675330B2 (en) 2020-04-01
KR102475363B1 (en) 2022-12-07
WO2015195567A1 (en) 2015-12-23
SG11201610536XA (en) 2017-01-27
CN106572996A (en) 2017-04-19
AU2015277406B2 (en) 2019-09-19
US9572807B2 (en) 2017-02-21
JP2017518330A (en) 2017-07-06
KR20170029509A (en) 2017-03-15

Similar Documents

Publication Publication Date Title
MX2021000609A (en) Methods of treatment with cyp3a4 substrate drugs.
EA201691845A1 (en) PHARMACEUTICAL COMPOSITIONS OF THERAPEUTICALLY ACTIVE COMPOUNDS
EA201690905A1 (en) SPECIFIC ANTIBODIES AGAINST CD38 FOR THE TREATMENT OF MALIGNANT NOROVATION IN HUMAN
MX2019012818A (en) Methods for improving memory and cognition and for treating memory and cognitive disorders.
MY186977A (en) Tetrasubstituted alkene compounds and their use
EA201691844A1 (en) PHARMACEUTICAL COMPOSITIONS OF THERAPEUTICALLY ACTIVE COMPOUNDS
PH12016502354A1 (en) Pharmaceutical composition
EA201791518A1 (en) METHODS TO TREAT DISEASES OF THE RETAIL
WO2019040106A3 (en) Compounds, salts thereof and their use in the treatment of diseases
SG10201811203TA (en) Protocols for treatment of major depressive disorder (mdd)
EA201692481A1 (en) COMBINATION CONTAINING GLUCOCORTICOID AND EDO-S101
TW201613578A (en) Pharmaceutical combinations
PH12017500392A1 (en) Medical treatments based on anamorelin
NZ745187A (en) 3-(carboxyethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
EA201892297A1 (en) METHODS FOR TREATING CHOLESTATIC AND FIBROTIC DISEASES
MX2022014792A (en) Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same.
WO2017011356A3 (en) Mcj inhibitors for use in treating drug-induced diseases and conditions
EA202193276A1 (en) METHODS FOR THE TREATMENT OF CHOLANGIOCARCINOMA
MX2019004804A (en) Treatment of prurigo nodularis.
BR112016023011A2 (en) gastric cancer treatment
MX2020008881A (en) Methods of treatment of cancer comprising chk1 inhibitors.
MX2017009608A (en) Anti-cancer compounds.
EP3549582A3 (en) Novel capsazepine analogs for the treatment of cancer and other proliferative diseases
MX2017013666A (en) Anti-fugetactic agent and immunotherapy agent combination therapy and compositions for the treatment of cancer.
EA202190226A1 (en) METHODS FOR TREATMENT OF HFpEF USING DAPAGLIFLOSIN AND COMPOSITIONS CONTAINING IT